Working to Eradicate Gynecologic Cancers

211 - Poster Session A
MK-2206 sensitizes BRCA2 mutant ovarian adenocarcinoma to cisplatin and poly ADP (adenosine diphosphate)-ribose polymerase (PARP) inhibitor therapy

Saturday, March 22, 2014: 9:25 AM
West Exhibit Hall (Tampa Convention Center)
M. E. Whicker, Z. P. Lin, A. C. Sartorelli and E. S. Ratner
Yale University School of Medicine, New Haven, CT
 
See more of: Poster Session A
See more of: Poster Session
<< Previous Presentation | Next Presentation >>